<DOC>
	<DOCNO>NCT01153750</DOCNO>
	<brief_summary>To test efficacy combination chemotherapy imatinib 5-FU advanced metastatic cholangiocellular carcinoma .</brief_summary>
	<brief_title>Efficacy Imatinib 5-FU/Leucovorin Patients With Advanced Carcinoma Gallbladder Bile Duct</brief_title>
	<detailed_description>Efficacy : Tumor assessment perform CT MRI scan , throughout study . All assessment perform within 14 day schedule day accord visit schedule , whenever clinically indicated otherwise . Radiological study must use technique use baseline . Evaluation base RECIST criterion . Safety : Safety assessment consist evaluate adverse event serious adverse event , laboratory parameter include hematology , chemistry , vital sign , physical examination , documentation concomitant medication and/or therapy .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Histologically/Cytologically confirm diagnosis advance / metastatic carcinoma gallbladder bile duct , unresectable metastatic therefore incurable conventional multimodality approach Performance status 0 , 1 2 ( ECOG ) Written , voluntary inform consent Age &gt; 18 year Adequate bone marrow function ( Granulocytes &gt; 1,5 x 109/l , Hb &gt; 10 g/dl , Platelets &gt; 100 x 109/l ) Adequate hepatic renal function ( bilirubin &lt; 1,25 x upper normal limit &lt; 1,5 x upper normal limit hyperbilirubinemia relate underlying disease , ALAT + ASAT &lt; 1,5 x upper normal limit , case liver metastases &lt; 5 x upper normal limit , creatinine &lt; 1,25 x upper normal limit ) Female patient childbearing potential must negative pregnancy test within 7 day initiation study drug dosing . Female patient childbearing potential must perform highly effective barrier method birth control throughout study proven efficacy &gt; 99 % . The contraception treatment perform additional six month follow discontinuation study treatment . Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . Male patient reproductive potential must agree employ effective barrier method birth control throughout study 6 month follow discontinuation study drug . Patient receive investigational agent within 28 day first day study drug dose . Patient &lt; 5 year free another primary malignancy , except : primary malignancy currently clinically significant require active intervention , primary malignancy basal cell skin cancer cervical carcinoma situ . Female patient pregnant breastfeeding . Patient severe and/or uncontrolled medical disease . The concurrent use warfarin acetaminophen allow imatinib mesylate need replace medication ( e.g . low molecular heparin case warfarin ) . Radiotherapy major abdominal thoracic surgery &lt; 4 week study entry ( exclude diagnostic biopsy port implantation ) Patient receive neoadjuvant imatinib mesylate fluoropyrimidines prior study entry Patient Grade III/IV cardiac problem define New York Heart Association Criteria . ( i.e. , congestive heart failure , myocardial infarction within 6 month study ) Known incompatibility imatinib,5FU , leucovorin Known brain metastasis Concurrent systemic chemotherapy , immunotherapy , hormone therapy History severe psychiatric illness Drug alcohol abuse Patient know chronic liver disease ( i.e. , chronic active hepatitis , cirrhosis ) Patients dihydropyrimidine dehydrogenase deficiency ( i.e . Treatment Zostex ) Patients associate dependent investigator sponsor Patients significant history noncompliance medical regimen inability grant reliable informed consent . Patients creatinine clearance &lt; 50ml/min . Patients severe decrease bone marrow function Patients acute infection Patients severe decrease liver function Patients reduce performance status ( ECOG &gt; 2 ) No active vaccination perform study treatment Anemia cause vitamin B12 deficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>cholangiocellular carcinoma</keyword>
	<keyword>bile duct cancer</keyword>
</DOC>